Suppr超能文献

妊娠期哮喘患者使用支气管扩张剂和皮质类固醇的安全性:我们已知晓的和我们需要做得更好的。

Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better.

机构信息

Department of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, Denmark.

出版信息

J Asthma Allergy. 2013 Nov 15;6:117-25. doi: 10.2147/JAA.S52592. eCollection 2013.

Abstract

Asthma is a common medical condition complicating pregnancy with potentially serious effects on pregnancy outcome. The aim of this review is to provide an update on efficacy and safety of asthma medications, primarily bronchodilators and corticosteroids, used during pregnancy with focus on pregnancy outcome, and, furthermore, to discuss limitations of available studies and point to possible improvements in future studies. A planned series of systematic searches was conducted using the PubMed database. Use of short-acting β2-agonists has generally been established as safe, and the few studies stating otherwise appear to have, perhaps critical, methodological limitations. The safety of long-acting β2-agonists remains to be further investigated, and the few available studies have methodological limitations and, therefore, provide no definite answers, although a very recent study supports the safety of add-on long-acting β2-agonists to inhaled corticosteroids. Inhaled corticosteroids are generally found to be safe, although further research is needed to investigate both the efficacy and safety of high dose therapy with inhaled corticosteroids. Studies have reported associations between the use of systemic corticosteroids and adverse perinatal outcomes, such as preterm birth, low birth weight, and pre-eclampsia. This must, however, be weighed against the potential serious impact of severe, uncontrolled asthma itself on pregnancy outcome. The main obstacle to a valid interpretation of several of the available studies is the inadequate stratification for asthma severity and control. Overall, asthma in itself and not just poor asthma control poses a greater risk to pregnancy outcomes than asthma medication. Nonetheless, more studies focusing on disentangling the effects of asthma alone and asthma medications are needed. Increased use of stratified risk assessments, taking the concept of asthma severity into greater consideration, is much warranted in future studies.

摘要

哮喘是一种常见的医学病症,会对妊娠结果产生潜在的严重影响。本综述的目的是提供最新的关于哮喘药物(主要是支气管扩张剂和皮质类固醇)在妊娠期间的疗效和安全性信息,重点关注妊娠结局,此外,还讨论了现有研究的局限性,并指出了未来研究可能的改进方向。我们使用 PubMed 数据库进行了一系列有计划的系统性搜索。短效β2-激动剂的使用一般被认为是安全的,而少数表明其不安全的研究似乎存在可能具有关键性的方法学局限性。长效β2-激动剂的安全性仍需进一步研究,少数可用的研究具有方法学局限性,因此无法提供明确的答案,尽管最近的一项研究支持将长效β2-激动剂添加到吸入皮质类固醇中作为附加治疗的安全性。吸入皮质类固醇一般被认为是安全的,尽管需要进一步研究来调查吸入皮质类固醇高剂量治疗的疗效和安全性。研究报告了使用全身皮质类固醇与不良围产期结局(如早产、低出生体重和子痫前期)之间的关联。然而,这必须与严重、不受控制的哮喘本身对妊娠结局的潜在严重影响相权衡。几个现有研究中存在的主要障碍是对哮喘严重程度和控制的分层不足。总的来说,哮喘本身而不仅仅是控制不佳的哮喘对妊娠结局的风险更大,而不是哮喘药物。尽管如此,仍需要更多的研究来关注单独区分哮喘和哮喘药物的影响。在未来的研究中,需要更多地使用分层风险评估,更加重视哮喘严重程度的概念。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验